Critical role of microenvironmental factors in angiogenesis

被引：56

作者：

Banfi A. ^{[1
,2
]}

von Degenfeld G. ^{[2
]}

Blau H.M. ^{[2
]}

机构：

[1] Department of Research, Basel University Hospital, 4031 Basel

[2] Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305-5175

来源：

Current Atherosclerosis Reports | 2005年 / 7卷 / 3期

关键词：

Vascular Endothelial Growth Factor; Hemangioma; Vascular Endothelial Growth Factor Expression; Vascular Endothelial Growth Factor Gene; Angiogenic Growth Factor;

D O I：

10.1007/s11883-005-0011-7

中图分类号：

学科分类号：

摘要：

Therapeutic angiogenesis, which entails the induction of new blood vessels by the delivery of angiogenic growth factors, is a highly attractive approach to the treatment of ischemic diseases. However, it is becoming increasingly clear that this is not easily achieved, as the effects of angiogenic growth factors can differ markedly depending on the timing of their expression, on the shape of the concentration gradients they form in vivo, and the interactions between endothelial cells and pericytes they induce. In fact, the same dose of vascular endothelial growth factor can induce stable, nonleaky, pericyte- covered normal capillaries or aberrant vascular structures that develop into hemangiomas. This difference in outcome can be due solely to the spatial characteristics of the delivery method. If delivery allows a homogeneous spatial distribution of VEGF in the microenvironment around each producing cell, angiogenesis can be therapeutic, whereas if the total dose is the average of diverse spatial levels, aberrant angiogenesis cannot be avoided. To achieve therapeutic angiogenesis, a means of regulating the microenvironmental levels of angiogenic factors will be critical to the generation of effective new treatment strategies. Copyright © 2005 by Current Science Inc.

引用

页码：227 / 234

页数：7

共 50 条

[1]

Blau H.M., Banfi A., The well-tempered vessel, Nat. Med., 7, pp. 532-534, (2001)

[2]

Semenza G.L., Targeting HIF-1 for cancer therapy, Nat. Rev. Cancer, 3, pp. 721-732, (2003)

[3]

Carmeliet P., Angiogenesis in health and disease, Nat. Med., 9, pp. 653-660, (2003)

[4]

Carmeliet P., Ferreira V., Breier G., Et al., Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele, Nature, 380, pp. 435-439, (1996)

[5]

Ferrara N., Carver-Moore K., Chen H., Et al., Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene, Nature, 380, pp. 439-442, (1996)

[6]

Miquerol L., Langille B.L., Nagy A., Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression, Development, 127, pp. 3941-3946, (2000)

[7]

Park J.E., Keller G.A., Ferrara N., The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF, Mol. Biol. Cell, 4, pp. 1317-1326, (1993)

[8]

Carmeliet P., Ng Y.S., Nuyens D., Et al., Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188, Nat. Med., 5, pp. 495-502, (1999)

[9]

Stalmans I., Ng Y.S., Rohan R., Et al., Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms, J. Clin. Invest., 109, pp. 327-336, (2002)

[10]

Ruhrberg C., Gerhardt H., Golding M., Et al., Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis, Genes Dev., 16, pp. 2684-2698, (2002)

← 1 2 3 4 5 →